Compass Therapeutics Investor Presentation Deck

Phase 2/3 U.S. BTC Study Design Patients who have received one prior line of therapy 2:1 Randomization COMPASS THERAPEUTICS CTX-009 + Paclitaxel n=100 Paclitaxel n=50 Study Treatment 28 Day Cycles CTX-009 10mg/kg Day 1 and 15 Paclitaxel 80 mg/m² Day 1, Day 8, and Day 15 of every 28 day cycle. Disease Progression per RECIST 1.1, as confirmed by Independent Central Radiology Follow Up Death, Lost to Follow Up, Withdrawal of Consent 24

View entire presentation